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Summary The antiproliferative effects of 5-azacytidine (acaCyd) and 5-aza-2'-deoxycytidine (azadCyd) were
studied in murine B16 melanoma and a series of B16 melanoma derived mutant strains with selective
resistances to the respective drugs. The in vitro cytotoxicities of azaCyd and azadCyd on B16 wild type,
expressed in terms of IC50 values, were found to be 5 1iM and 0.2,uM, respectively. The in vitro cytotoxity of
both drugs was dependent on the duration of exposure. Uridine and cytidine were able to reverse the in vitro
cytotoxicity of azaCyd, but not of azadCyd. Conversely, 2'-deoxycytidine was able to reverse the cytotoxic
effect of azadCyd but not of azaCyd. Thymidine and 2'-deoxyuridine had no detectable effects on the in vitro
cytotoxicity of either azaCyd or azadCyd. B16 melanoma mutant strains that were selected for resistance to
azaCyd showed no cross-resistance to azadCyd, cytosine arabinoside or the fluorinated pyrimidine analogues
FUrd, FCyd, FdUrd and FdCyd. Mutant strains that were selected for resistance to azadCyd showed no
cross-resistance to azaCyd or fluorinated pyrimidine analogs, but only to cytosine arabinoside. The combined
data suggest that azaCyd and azadCyd follow different routes of intracellular metabolic activation and exert
their cytotoxic activity via different intracellular targets.
5-azacytidine (azaCyd), a cytidine derived antineoplastic
agent, was first synthesised about 25 years ago (Piskala et
al., 1964) and was later isolated from the organism Strepto-
verticillium ladakanus (Hamka et al., 1966; Bergy et al.,
1966). The cytotoxic mechanism of azaCyd appeared to be
polyvalent and several cellular metabolic pathways have been
proposed to be affected, including the activities of S-adeno-
sylmethionine methyltransferase and orotidine-5'-
monophosphate decarboxylase (Cihak, 1974; Christman et
al., 1983).
Presently the cytotoxic action of azaCyd has been
proposed to be predominantly based on the induction of a
severe hypomethylation of DNA and RNA as a result of the
incorporation of the azaCyd residues into newly synthesised
DNA and RNA, where azaCyd is unable to act as a methyl
group acceptor (Walker & Shay, 1984). Furthermore,
Christman et al., (1985) found that DNA containing azaCyd
residues had an altered protein binding capacity with respect
to its interaction with a variety of non-histone nuclear
proteins, including methyltransferases. The latter pheno-
menon also contributed to the hypomethylation of the DNA
in azaCyd treated cells.
It is now generally agreed that the degree of DNA
methylation is involved in the regulation of gene expression,
thereby playing an important role in the control of cellular
metabolisms (Razin et al., 1980; Jones et al., 1980; Jones,
1986). Indeed, when azaCyd was administered to human
promyelocytic leukaemia cells HL 60, these presented a more
differentiated phenotype (Christman et al., 1983). T984-15
cells, a differentiation defective myogenic cell line, regained
the ability to form myogenic colonies after treatment with
azaCyd (Walker et al., 1984). When mouse embryo cells
C34/lOTI/2c18 were grown in the presence of azaCyd, they
produced biochemically differentiated myotubes, adipocytes
and chondrocytes (Taylor et al., 1982). These findings
corroborated the assumption that azaCyd may exert its
activity indirectly on a number of enzymes or macro-
molecules. Evidently, the metabolic pathway and mode of
action of azaCyd is very complicated and not yet fully
understood. Yet, despite this limited knowledge on its
mechanism of activity, azaCyd has successfully been used for
the treatment of acute myelogenous leukaemia (Von Hoff et
al., 1977).
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Also the deoxy-analogue of azaCyd, 5-aza-2'-deoxycytidine
(azadCyd) induced hypomethylation of DNA and differen-
tiation and appeared to be cytotoxic in Friend erythro-
leukaemic cells (Creusot et al., 1982), although azadCyd
exerted its activity at substantially lower concentrations
than azaCyd (Constantinides et al., 1978). These comparable
effects on intracellular events have led to the assumption
that azaCyd and azadCyd belong to the same class of
antineoplastic agents with similar mechanisms of cytotoxic
activity.
To verify this hypothesis, the modes of action of both
azaCyd and azadCyd were studied in B16 melanoma cells,
by means of rescue experiments with different nucleosides
and the characterisation of a number of B16 melanoma
derived mutant strains with selective resistancies to the
respective drugs. Evidence was provided that azaCyd and
azadCyd followed different routes of activation and exerted
their cytotoxic activity on different intracellular targets,
without sharing any common metabolism. These findings
indicated that azadCyd may represent a new anticancer
agent that is fundamentally different from azaCyd.
Materials and methods
Chemicals
The pyrimidine nucleosides dThd, Cyd, dCyd, azaCyd and
azadCyd were obtained from the Sigma Chemical Company
(St Louis, Michigan, USA). The fluorinated pyrimidine analogs
FCyd, FdCyd, FUrd and FdUrd were kindly provided by
F. Hoffmann-LaRoche Ltd (Basel, Switzerland). Cytosine-
arabinoside (araC) was a product ofUpjohn (Puurs, Belgium).
Medium RPMI 1640, foetal calf serum, streptomycin,
penicillin and amphotericin were purchased from Gibco
Europe (Paisley, United Kingdom). 3-(4,5-dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide (MTT) was obtained
from Aldrich Europe (Brussels, Belgium). All other chemicals
were reagent grade.
Cell culture
B16 melanoma cells were grown as a monolayer in culture
medium RPMI 1640, supplemented with 10% (v/v) foetal
calf serum, 1 mM glutamine, 25 jgml -1 penicillin, 25 jugml
streptomycin and 50 ,igml - amphotericin.
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In vitro cytotoxicity assays
The effects of antineoplastic agents on B16 melanoma cell
proliferation were measured as follows. Cells (5 x 103) were
cultured in 96 well microtitre plates as described above in
150pl of medium, in the continuous presence of varying
concentrations of antimetabolites, as indicated in the legends
to the figures. After a period of 5 days of culture in a 5%
(v/v) CO2 atmosphere, the relative survival was measured by
the residual capacity to reduce tetrazolium salts (Mosmann,
1983). Briefly, to each well 10lp of a 0.5% (w/v) MTT in
PBS was added, followed by an incubation of 2h at 37°C.
The culture medium was removed carefully and the
formazan deposit was dissolved by addition of lOO1p1 of 10%
(v/v) Triton-XI00 in 2-propanol. The absorbances at 540nm
were measured with a Titertek Multiscan (Flow
Laboratories, Irvine, United Kingdom). The percentage
survival in a given incubation was calculated from the
equation:
O-
percentage survival = 100 . (A54O0 - A5400)/(A540C -A5400)
in which A540', A540C and A540') are the mean of duplicate
absorbance values at 540nm of, respectively, the incubation
to be assayed, the untreated control and the background
value as obtained in the absence of cells. Test results are the
mean of duplicate incubations with an average standard
error of the mean of 8%. The in vitro cytotoxic effects are
expressed as the inhibitory concentration 50 (IC50), i.e. the
concentration of drug that leads to 50% inhibition of cell
proliferation.
Rescue experiments
In case of rescue experiments, the cytotoxic effects of azaCyd
and azadCyd were determined in the continuous presence of
varying concentrations of different nucleosides as indicated
in the legends to the figures, under otherwise identical
conditions. The rescue effect was expressed as an increase in
IC50 value (dIC50), defined by the following equation:
dIC50 =IC50(+nucleoside)/IC50(- nucleoside)
Mutation induction and mutant isolation
B16 melanoma cells were pulse treated with ethylmethane
sulphonate (EMS) for a period of 3 h at 37°C. Subsequently,
the cells were washed twice and cultured for 10 days in the
absence of mutagen or antineoplastic agents. The cells were
then selected for resistance to azaCyd or azadCyd by culture
in medium supplemented with the respective antimetabolites.
The concentration of drug was increased stepwise up to 100
times the IC50 value of Bl6 wild type cells for the respective
cytotoxic agents. Subsequently, the heterogenous populations
of azaCyd or azadCyd resistant mutant strains of B16
melanoma cells were subjected to clonal purification, using
conditions as described by Hamburger and Salmon (1977).
Individual colonies of 100 to 200,pm were plucked from the
agar medium, subcultured in liquid medium and screened for
resistance to azaCyd and azadCyd as described above. The
resistance coefficient (Rc) of a given mutant strain was






Figure 1 (a) Effects ofazaCyd and azadCyd on the proliferation
of BJ6 melanoma cells. B16 melanoma cells were seeded in a 96
well microtiter plate (5 x 103 cells per well) and were allowed to
adhere for a period of 24h at 37°C. Subsequently, varying
concentrations of azaCyd (0) or azadCyd (-) were added and
the effect on cell proliferation measured as described in Materials
and methods. Alternatively, varying concentrations of azaCyd
(0) or azadCyd (l) were added immediately after trypsinisation
and their cytotoxic effect was measured under otherwise identical
conditions. (b) The effects of the duration of drug treatment on
the cytotoxic effects of azaCyd and azadCyd. The effects of 1 h
pulse treatment (0, Cl) or continuous exposure (H,) with
varying concentrations of azaCyd (0,0) or azadCyd (El, *) on
the in vitro proliferation of B16 melanoma cells were measured as
described in Materials and methods.
Rc =IC50 (mutant strain)/IC50(B16 wild type)
Results
To determine to what extent azaCyd and azadCyd exerted a
cytotoxic effect on B16 melanoma, the proliferation of B16
melanoma cells was measured in the presence of varying
concentrations of the respective antimetabolites under
different experimental conditions. The experiments of Figure
I (A), (B) showed a marked difference in in vitro cytotoxicity
between azaCyd and azadCyd, with IC50 values of
S x 10 -6M and 2 x 10 - M, respectively. Figure 1(A) shows
that the in vitro cytotoxic effects were not conditioned by
growth conditions (monolayer or suspension). A pronounced
variation was found in the in vitro cytotoxicity as a function
of the duration of drug treatment (Figure 1(B)). Both
azaCyd and azadCyd were more effective in continuous
exposure than in pulse treatment.
Indications of the modes of action of azaCyd and
azadCyd on B16 melanoma cells were obtained by rescue
I O)nAZACYTIDINES AS ANTINEOPLASTIC AGENTS 263
experiments with Thd, Cyd, Urd, dCyd and dUrd. As shown
in Figure 2(A), dThd was not able to diminish the cytotoxic
action of either azaCyd or azadCyd, suggesting that dThd
metabolism was not affected by these drugs. Different
observations were made when the effects of Cyd (Figure
2(B)) and Urd (Figure 2(C)) and their 2'-deoxy analogues,
dCyd (Figure 2(D)) and dUrd (Figure 2(E)), were measured.
Both Cyd and Urd were able to reverse the cytotoxic action
of azaCyd, but not of azadCyd. Opposite effects were
observed in the case of dCyd, which was able to partially
rescue from azadCyd toxicity but not from azaCyd toxicity.
No significant rescue was observed with dUrd.
To study possible differences in the modes of action of
azaCyd and azadCyd in more detail, mutant strains of B16
melanoma cells with selective resistances to the respective
drugs were isolated and characterized. The resistance
coefficients of azadCyd selected mutants were 2 to 3 logs
higher than those of azaCyd selected mutant strains (Table
I). With the exception of strain 6116a, none of the azaCyd
resistant mutant strains showed any notable cross-resistance
to azadCyd. Conversely, mutant strains that were selected
for resistance to azadCyd showed an unaltered sensitivity to
azaCyd.
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Figure 2 The effect ofpyrimidine nucleosides on the cytotoxic effects ofazaCyd and azadCyd. The cytotoxic effects of azaCyd and
azadCyd on B16 melanoma cells were measured as described in the legend to Figure l(a), in the continuous presence of varying
concentrations of dThd (panel a), Cyd (panel b), Urd (panel c), dCyd (panel d), or dUrd (panel e). Thelncrease in IC50 value
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Table I Effects of azaCyd and azadCyd on the proliferation of mutant strains of B16
melanoma
Cell line Rc(azaCyd) Rc(azadCyd) Cell line Rc(azaCyd) Rc (azadCyd)
B16 1 I B16 1 1
6111 60 5 7101 1 5000
6116a 60 15 7102 6 15000
6116b 8 2 7103 4 >30000
6120 16 3 7112 4 10000
6123 4 0.5 7116 2 >30000
6130 14 5 7121 - 2 >30000
The strains 6111, 6116a, 6116b, 6120, 6123 and 6130 were selected for resistance to
azaCyd and the strains 7101, 7102, 7103, 7112, 7116 and 7121 for resistance to azadCyd.
The sensitivity of the respective mutant strains for azaCyd and azadCyd was determined
as described in the legend of Figure 1. The resistance coefficients (Rc) were defined as
defined in Materials and methods.
Table II Effect of fluorinated pyrimidine analogs and cytosine arabinoside on the
proliferation of mutant strains of B16 melanoma
Cell line Rc(FUrd) Rc(FCyd) Rc(FdUrd) Rc(FdCyd) Rc(araCyt)
6111 1 1 4 0.4 1
6116a 1 1 1.5 0.2 1
6116b 1 1 1.5 0.4 1
6120 1 1 4.5 0.1 1
6123 1 1 4.5 0.2 1
6130 1 1 3.5 1 1
7101 0.3 0.3 20 40 790
7102 0.3 0.5 1 40 710
7103 0.3 0.5 5 80 630
7112 0.3 0.3 2 16 630
7116 0.3 5 1 16 875
7121 0.3 0.4 1 12 1400
The sensitivities of the respective mutant strains for the fluoropyrimidines
FUrd, FCyd, FdUrd, FdCyd and for araCyt and the respective resistance
coefficients were determined as described in the legend to Table I.
responsible for the induced resistance to the respective
antimetabolites involved drug transport or drug activation,
the different mutant strains were screened for cross-resistance
to other Cyd and Urd analogues. As shown in Table II,
none of the azaCyd resistant mutant strains showed any
cross-resistance to Furd, FCyd or their 2'deoxy analogues.
Comparable observations were made for the azadCyd
resistant mutant strains, which showed no cross-resistance to
FCyd, FUrd or FdUrd and only a moderate cross-resistance
to FdCyd. Only for araCyt was an extreme cross-resistance
observed, but only in those mutant strains that were selected
for resistance to azadCyd.
Discussion
The cytidine derived antileukaemic agents azaCyd and
azadCyd have long since been considered to belong to the
same class of antineoplastic agents. Their modes of action
have been proposed to be based on an induction of hypo-
methylation of DNA. The present paper described a study of
the in vitro effects of azaCyd and azadCyd in B16 melanoma
cells and B16 melanoma derived mutant strains with selective
resistances to the respective drugs. In vitro antiproliferation
studies in liquid medium were preferred over colony forming
assays, since the former methodology has the advantage of
measuring the effect of drugs on the entire tumour cell
population, rather than on the minute amount of clonogenic
cells (Weisenthal, 1985). Moreover, in combination with dye
reduction for growth assessment (Mossmann, 1983) it is a
very convenient method to perform reproducible dose-
response curves.
Our data showed that specifically azadCyd exerted a
pronounced inhibitory effect on the proliferation of B16
melanoma cells in vitro, thereby suggesting a potential effect
of azadCyd on solid tumours. Furthermore, this finding
confirmed the notion that azadCyd exerts its cytotoxic
activity at substantially lower concentrations than azaCyd
(Constantinides et al., 1987; Creusot et al., 1982).
Initial indications with respect to the in vitro modes of
action of the respective antimetabolites were obtained via
rescue experiments. It is assumed that if a given pyrimidine
nucleoside and an antimetabolite share a common metabolic
pathway, this nucleoside will reduce the in vitro cytotoxicity
via competitive inhibition of either drug uptake or drug
activation. Contrary to azadCyd, the cytotoxic effects of
azaCyd could be reversed by Cyd and Urd, but not by the
deoxynucleosides dThd, dCyd and dUrd. This observation is
explicable by the facts that azaCyd uptake is mediated by
the Urd/Cyd transport system and that azaCMP formation
is catalysed by Urd/Cyd kinase. In this respect, Urd and Cyd
would act as competitive inhibitors of the formation of
intracellular azaCMP. An alternative explanation could be
that azaCyd exerted its activity after deamination to azaUrd,
where Urd and Cyd would act as competitive inhibitors of
this conversion.
Comparable effects were observed for azadCyd, whose
cytotoxicity could only be reversed with dCyd, but not with
Urd and Cyd, nor with dThd and dUrd. Again, the most
likely explanation is an inhibition of azadCyd uptake and
phosphorylation by dCyd. The combined data indicated that
azaCyd and azadCyd followed different routes of intra-
cellular activation and should in this respect be considered as
different antineoplastic agents in B16 melanoma.AZACYTIDINES AS ANTINEOPLASTIC AGENTS 265
Differences in the modes of action of azaCyd and
azadCyd were also observed in the characterisation of B16
melanoma mutant strains with selective resistances to the
respective cytotoxic agents. Mutant strains that were selected
for resistance to azaCyd showed non-existent or only a
negligible cross-resistance to azadCyd. This observation
could also be explained by differences in transport and
phosphorylation of both drugs. However, cross-resistance
was also not observed for Furd and FCyd, fluorinated
pyrimidine analogs that share a common route of activation
with azaCyd. These findings exclude mutations at the level
of nucleoside transport or phosphorylation. Thus, the
different mutant strains were not hampered in the intra-
cellular formation of the active metabolites of azaCyd. For
this reason, the present findings lead us to the conclusion
that the induced resistance is based on an altered intra-
cellular target for azaCyd. Therefore, the lack of cross-
resistance to azadCyd would imply that azaCyd and
azadCyd act on different intracellular targets.
Comparable observations were made for azadCyd resistant
mutant strains, which showed only a moderate cross-
resistance to FdCyd and FdUrd, thereby excluding an
altered intracellular azadCyd metabolism. Again, the lack of
any cross-resistance to azaCyd indicated that azaCyd and
azadCyd exerted their cytotoxic effects at different
intracellular targets. The only significant cross-resistance that
was observed was when azadCyd resistant mutant strains
were exposed to araCyt. The latter drug exerts its activity at
the level of DNA synthesis by inactivating DNA polymerase
and is activated via the dCyd pathway (Tattersall et al.,
1974; Wiley, 1982; Riva et al., 1985). Therefore, the results
of the present study indicate that with respect to their modes
of action, azadCyd is more related to araCyt than to
azaCyd.
In summary, the present study showed that azaCyd and
azadCyd should be considered as fundamentally different
antineoplastic agents. In B16 melanoma, they are activated
via different intracellular metabolic pathways and interact
with different intracellular targets. Both azaCyd and
azadCyd may exert their activity via an induction of DNA
hypomethylation, but it seems plausible that this effect is
achieved in a different manner. Therefore, a more detailed
unravelling of the differences in the modes of action of
azaCyd and azadCyd will remain the subject of further
investigation.
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